Latest Commercial Rollouts News

Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.

EBR Systems accelerated its U.S. commercial rollout of the WiSE CRT System in Q1 2026 with implant volumes more than doubling and revenue hitting US$2.4 million. The company also secured a key regulatory milestone in Australia with TGA Priority Review, yet losses deepened and cash burn intensified, raising fresh questions about its funding runway.

BCAL Diagnostics appoints Anne-Louise Arnett as CEO effective June 2026, aiming to accelerate its commercial rollout and international market entry of early cancer detection tests.

Swift TV Ltd has landed its inaugural hospitality contract with Daydream Island Resort, deploying its in-room platform across 244 rooms and marking a strategic expansion beyond resources and aged care sectors.

Swift TV has gained final Netflix approval after a multi-year certification, becoming Australia’s sole enterprise Connective TV platform with direct Google Play Store access. This integration bolsters its foothold in sectors demanding seamless consumer streaming with robust enterprise controls.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.

Green360 Technologies has kicked off commercial production of its low-carbon Eco-Clay cement alternative through a capital-light tolling agreement with Calix, while securing federal grant funding and a $4.5 million placement to fuel growth.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Control Bionics progresses its scalable distributor-led model in North America, inks a strategic US partnership for iOS speech devices, and gains German reimbursement eligibility for NeuroNode, while managing cash flow amid NDIS delays.

One Click Group delivered a remarkable 1000% increase in new users and a 64% reduction in acquisition costs in Q1 2026, setting the stage for strong revenue growth ahead of tax season.

Epiminder has ramped up enrolment in its DETECT study, contracting 18 US medical centres and maintaining a robust $83.8 million cash position to fund its Minder device commercialisation through 2028.